Low-dose alemtuzumab induction in a tailored immunosuppression protocol for sensitized kidney transplant recipients

BACKGROUND: Induction therapy is crucial in kidney transplantation and constitutes an important cornerstone for long-term allograft survival. Alemtuzumab is a depleting CD52-specific antibody with T- and B-cell activity, leading to prolonged lymphocyte depletion for up to 12 months, with profound im...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:BMC Nephrol
Hlavní autoři: Guthoff, Martina, Berger, Kilian, Althaus, Karina, Mühlbacher, Thomas, Bakchoul, Tamam, Steurer, Wolfgang, Nadalin, Silvio, Königsrainer, Alfred, Heyne, Nils
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2020
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7218828/
https://ncbi.nlm.nih.gov/pubmed/32404066
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12882-020-01767-z
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky